Studies how well people with high cholesterol keep taking PCSK9 inhibitor drugs in Italy
Follows adults with high cholesterol taking evolocumab or alirocumab in daily practice.
Plain-language title generated from the registry record
Registry title: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Key facts
- Where
- Arzignano, Bari, Caserta, Catanzaro, Eboli, Foggia, Genova, Lecce, Messina, Milan, Naples, Novara, Parma, Pescara, Rivoli, Roma, Salerno, Sassari, Siena, and Torino, ItalySee the 27 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05430828, who can take part
Where in Italy
- Ospedali dell'Ovest VicentinoArzignano, ItalyTaking people
- University Of Bari Aldo MoroBari, ItalyTaking people
- University of Campania "Luigi Vanvitelli"Caserta, ItalyTaking people
- University Magna Graecia of CatanzaroCatanzaro, ItalyTaking people
- Presidio Ospedaliero Maria SS AddolorataEboli, ItalyTaking people
- Policlinico Riuniti FoggiaFoggia, ItalyTaking people
- Università degli Studi di GenovaGenova, ItalyTaking people
- Ospedale di LecceLecce, ItalyTaking people
- Università degli Studi di MessinaMessina, ItalyTaking people
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- Policlinico di Milano Ospedale Maggiore | Fondazione IRCCS Ca' GrandaMilan, ItalyTaking people
- AORN dei Colli - Ospedale monaldiNaples, ItalyTaking people
- Federico II University of Naples, Department of Advanced Biomedical SciencesNaples, ItalyTaking people
- Federico II University of Naples, Department of Translational Medical SciencesNaples, ItalyTaking people
- University of Naples Federico II, Department of Clinical Medicine and SurgeryNaples, ItalyTaking people
- Azienda Ospedaliero Universitaria Maggiore della CaritàNovara, ItalyTaking people
- Azienda Ospedaliero-Univeristaria di ParmaParma, ItalyTaking people
- Presidio Ospedaliero PescaraPescara, ItalyTaking people
- Ospedale di RivoliRivoli, ItalyTaking people
- Azienda Ospedaliera San Camillo ForlaniniRoma, ItalyTaking people
- Policlinico CasilinoRoma, ItalyTaking people
- Policlinico Tor VergataRoma, ItalyTaking people
- Sapienza University of RomeRoma, ItalyNo longer taking part
- Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'AragonaSalerno, ItalyTaking people
- Ospedale SS Annunziata A.O.U.Sassari, ItalyTaking people
- University of SienaSiena, ItalyTaking people
- Azienda Ospedaliera Ordine Mauriziano TorinoTorino, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Federico II University
- Trial code
- NCT05430828
- Record updated
- 22 January 2026
- Original description
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.Read full original descriptionShow less
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Inclusion: Patients under PCSK9 inhibitor treatment.
Exclusion: Age < 18 years o > 80 years; Patients who refuse to participate and to sign informed consent.